# Clinical trial results:
# A Double-Blind, Placebo-Controlled Pivotal Phase III Study Evaluating Xilonix in Symptomatic Colorectal Cancer Patients Refractory to Standard Therapy

## Summary

| | |
|---|---|
| EudraCT number | 2014-000550-12 |
| Trial protocol | HU GB PL DE CZ BG |
| Global end of trial date | 03 November 2015 |

### Results information

| | |
|---|---|
| Result version number | v1 |
| This version publication date | 18 April 2021 |
| First version publication date | 18 April 2021 |

## Trial information

### Trial identification

| | |
|---|---|
| Sponsor protocol code | 2014-PT026 |

### Additional study identifiers

| | |
|---|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT02138422 |
| WHO universal trial number (UTN) | - |

Notes:

### Sponsors

| | |
|---|---|
| Sponsor organisation name | XBiotech Germany GmbH |
| Sponsor organisation address | 8201 E Riverside Drive, Building 4, Suite 100, Austin, Germany, 78744 |
| Public contact | Clinical Trial Information, XBiotech Germany GmbH, info@xbiotech.com |
| Scientific contact | Clinical Trial Information, XBiotech Germany GmbH, info@xbiotech.com |

Notes:

### Paediatric regulatory details

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Final |
| Date of interim/final analysis | 03 November 2015 |
| Is this the analysis of the primary completion data? | No |

| | |
|---|---|
| Global end of trial reached? | Yes |
| Global end of trial date | 03 November 2015 |
| Was the trial ended prematurely? | No |

Notes:

## General information about the trial

Main objective of the trial:

The primary purpose of the study was to evaluate objective response rate (ORR), a composite measure assessing change in Lean Body Mass (LBM), fatigue, pain, and appetite from baseline to week 8.

Protection of trial subjects:

The study was performed in accordance with the current version of the declaration of Helsinki (64th world medical association [WMA] General Assembly, Fortaleza, Brazil, October 2013). Safety assessment included Adverse events, hematology, and chemistry labs.

Background therapy: -

Evidence for comparator: -

| | |
|---|---|
| Actual start date of recruitment | 20 March 2014 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | Bulgaria: 14 |
| Country: Number of subjects enrolled | Czechia: 32 |
| Country: Number of subjects enrolled | France: 12 |
| Country: Number of subjects enrolled | Georgia: 19 |
| Country: Number of subjects enrolled | Hungary: 28 |
| Country: Number of subjects enrolled | Poland: 164 |
| Country: Number of subjects enrolled | Russian Federation: 23 |
| Country: Number of subjects enrolled | United Kingdom: 17 |
| Worldwide total number of subjects | 309 |
| EEA total number of subjects | 250 |

Notes:

### Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |

| | |
|---|---|
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 172 |
| From 65 to 84 years | 137 |
| 85 years and over | 0 |

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 458 subjects were screened and 333 were randomized.

### Period 1

| | |
|---|---|
| Period 1 title | Blinded Study |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator |

### Arms

| | |
|---|---|
| Are arms mutually exclusive? | Yes |
| **Arm title** | Placebo Controlled Period (CP) plus BSC |

Arm description:

Subjects received matching Placebo via intravenous (IV) injection once every 2 weeks (one cycle) for a total of 4 infusions (four cycles). Best supportive care (BSC) is defined as those measures intended to provide palliation of symptoms and improve quality of life. This included, but is not limited to, psychological support, dietary advice, exercise advice, antibiotics, anti-emetics, and analgesia.

| | |
|---|---|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intravenous use |

Dosage and administration details:

Subjects received IV injection of matching Placebo.

| | |
|---|---|
| **Arm title** | Bermekimab (Xilonix) plus BSC |

Arm description:

Subjects received an intravenous (IV) injection of Bermekimab 7.5 milligrams per kilograms (mg/kg) once every 2 weeks (Cycle 1) for a total of 4 infusions (four cycles). BSC is defined as those measures intended to provide palliation of symptoms and improve quality of life. This included, but is not limited to, psychological support, dietary advice, exercise advice, antibiotics, anti-emetics, and analgesia.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Bermekimab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intravenous use |

Dosage and administration details:

Subjects received IV injection of Bermekimab 7.5 mg/kg.

| Number of subjects in period 1 | Placebo Controlled Period (CP) plus BSC | Bermekimab (Xilonix) plus BSC |
|---|---|---|
| Started | 102 | 207 |
| Completed | 83 | 167 |
| Not completed | 19 | 40 |
| Adverse event, serious fatal | 5 | 9 |
| Physician decision | 3 | 6 |
| Consent withdrawn by subject | 1 | 5 |
| Adverse event, non-fatal | 3 | 3 |
| Other | 3 | 10 |
| Lost to follow-up | - | 3 |

## Period 2

| | |
|---|---|
| Period 2 title | Open Label Extension |
| Is this the baseline period? | No |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

## Arms

| | |
|---|---|
| Are arms mutually exclusive? | Yes |
| **Arm title** | Placebo to Bermekimab (after CP) |

Arm description:

Subjects who received Placebo at Week 0, 2, 4, and 6 in CP received Bermekimab 7.5 mg/kg IV injection at Week 8 and every two weeks onwards.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Bermekimab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intravenous use |

Dosage and administration details:

Subjects received Bermekimab 7.5 mg/kg IV injection.

| | |
|---|---|
| **Arm title** | Bermekimab (after CP) |

Arm description:

Subjects who received Bermekimab in CP were randomized to the control arm received IV placebo at 7.5 mg/kg via IV injection once every 2 weeks (one cycle) for a total of 4 infusions (four cycles).

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Bermekimab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intravenous use |

Dosage and administration details:

Subjects received Bermekimab 7.5 mg/kg IV injection.

| **Number of subjects in period 2[1]** | Placebo to Bermekimab (after CP) | Bermekimab (after CP) |
|---|---|---|
| Started | 62 | 138 |
| Completed | 1 | 2 |
| Not completed | 61 | 136 |
| Adverse event, serious fatal | 9 | 22 |
| Physician decision | 14 | 31 |
| Consent withdrawn by subject | 17 | 34 |
| Adverse event, non-fatal | 2 | 10 |
| Other | 16 | 32 |
| Protocol terminated | 2 | - |
| Lost to follow-up | - | 2 |

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.
Justification: Subjects who completed treatment period and opted to continue treatment entered in to the open label extension phase.

## Baseline characteristics

| Reporting groups | |
|---|---|
| Reporting group title | Placebo Controlled Period (CP) plus BSC |
| Reporting group description: | |
| Subjects received matching Placebo via intravenous (IV) injection once every 2 weeks (one cycle) for a total of 4 infusions (four cycles). Best supportive care (BSC) is defined as those measures intended to provide palliation of symptoms and improve quality of life. This included, but is not limited to, psychological support, dietary advice, exercise advice, antibiotics, anti-emetics, and analgesia. | |
| Reporting group title | Bermekimab (Xilonix) plus BSC |
| Reporting group description: | |
| Subjects received an intravenous (IV) injection of Bermekimab 7.5 milligrams per kilograms (mg/kg) once every 2 weeks (Cycle 1) for a total of 4 infusions (four cycles). BSC is defined as those measures intended to provide palliation of symptoms and improve quality of life. This included, but is not limited to, psychological support, dietary advice, exercise advice, antibiotics, anti-emetics, and analgesia. | |

| Reporting group values | Placebo Controlled Period (CP) plus BSC | Bermekimab (Xilonix) plus BSC | Total |
|---|---|---|---|
| Number of subjects | 102 | 207 | 309 |
| Title for AgeCategorical<br>Units: subjects | | | |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 60 | 112 | 172 |
| From 65 to 84 years | 42 | 95 | 137 |
| 85 years and over | 0 | 0 | 0 |
| Title for AgeContinuous<br>Units: years | | | |
| arithmetic mean | 62.6 | 63.3 | |
| standard deviation | ± 9.21 | ± 10.08 | - |
| Title for Gender<br>Units: subjects | | | |
| Female | 43 | 79 | 122 |
| Male | 59 | 128 | 187 |

## End points

### End points reporting groups

| | |
|---|---|
| Reporting group title | Placebo Controlled Period (CP) plus BSC |
| Reporting group description: | |
| Subjects received matching Placebo via intravenous (IV) injection once every 2 weeks (one cycle) for a total of 4 infusions (four cycles). Best supportive care (BSC) is defined as those measures intended to provide palliation of symptoms and improve quality of life. This included, but is not limited to, psychological support, dietary advice, exercise advice, antibiotics, anti-emetics, and analgesia. | |
| Reporting group title | Bermekimab (Xilonix) plus BSC |
| Reporting group description: | |
| Subjects received an intravenous (IV) injection of Bermekimab 7.5 milligrams per kilograms (mg/kg) once every 2 weeks (Cycle 1) for a total of 4 infusions (four cycles). BSC is defined as those measures intended to provide palliation of symptoms and improve quality of life. This included, but is not limited to, psychological support, dietary advice, exercise advice, antibiotics, anti-emetics, and analgesia. | |
| Reporting group title | Placebo to Bermekimab (after CP) |
| Reporting group description: | |
| Subjects who received Placebo at Week 0, 2, 4, and 6 in CP received Bermekimab 7.5 mg/kg IV injection at Week 8 and every two weeks onwards. | |
| Reporting group title | Bermekimab (after CP) |
| Reporting group description: | |
| Subjects who received Bermekimab in CP were randomized to the control arm received IV placebo at 7.5 mg/kg via IV injection once every 2 weeks (one cycle) for a total of 4 infusions (four cycles). | |

### Primary: Objective Response Rate (ORR) for mITT population

| | |
|---|---|
| End point title | Objective Response Rate (ORR) for mITT population |
| End point description: | |
| Objective response was defined as improvement or stabilization (greater than or equal to [>=] 0 kilograms [kg] change) of Lean Body Mass (LBM) as assessed by Dual-energy X-ray Absorptiometry (DEXA) scan; and improvement or no worsening (>=0 score point change) on any two of the three symptom scale measures (fatigue, pain, appetite) of European Organization for Research and Treatment of Cancer – Quality of Life Questionnaire (EORTC QLQ-C30). Modified intent-to-treat (mITT) population was defined as all randomized subjects who received at least one infusion of the study drug. | |
| End point type | Primary |
| End point timeframe: | |
| Up to 8 weeks | |

| End point values | Placebo Controlled Period (CP) plus BSC | Bermekimab (Xilonix) plus BSC | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 102 | 207 | | |
| Units: Subjects | | | | |
| number (not applicable) | 19 | 33 | | |

### Statistical analyses

| Statistical analysis title | Statistical analysis 1 |
|---|---|
| Comparison groups | Placebo Controlled Period (CP) plus BSC v Bermekimab (Xilonix) plus BSC |
| Number of subjects included in analysis | 309 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority |
| P-value | = 0.004 |
| Method | Pearson Chi-Square test |
| Parameter estimate | Unadjusted Odds Ratio |
| Point estimate | 2.14 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 1.21 |
| upper limit | 3.78 |

## Primary: ORR for per Protocol Population

| End point title | ORR for per Protocol Population |
|---|---|

End point description:

Objective response was defined as improvement or stabilization (>= 0 kg change) of LBM as assessed by DEXA scan; and improvement or no worsening (>=0 score point change) on any two of the three symptom scale measures (fatigue, pain, appetite) of EORTC QLQ-C30. Per protocol population set excluded the 24 subjects who were randomized but not dosed and the 17 placebo subjects from mITT population who showed significant level of MABp1 concentration at PK assessment.

| End point type | Primary |
|---|---|

End point timeframe:

Up to 8 weeks

| End point values | Placebo Controlled Period (CP) plus BSC | Bermekimab (Xilonix) plus BSC | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 85 | 207 | | |
| Units: Subjects | | | | |
| number (not applicable) | 19 | 68 | | |

## Statistical analyses

| Statistical analysis title | Statistical analysis 1 |
|---|---|
| Comparison groups | Placebo Controlled Period (CP) plus BSC v Bermekimab (Xilonix) plus BSC |

| | |
|---|---|
| Number of subjects included in analysis | 292 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority |
| P-value | = 0.037 |
| Method | Pearson Chi-Square test |
| Parameter estimate | Unadjusted Odds Ratio |
| Point estimate | 1.7 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.94 |
| upper limit | 3.06 |

## Secondary: Change from Baseline in Interleukin-6 (IL-6) up to 8 Weeks

| | |
|---|---|
| End point title | Change from Baseline in Interleukin-6 (IL-6) up to 8 Weeks |

End point description:

Change in IL-6 up to 8 weeks was analyzed. mITT population was defined as all randomized subjects who received at least one infusion of the study drug.

| | |
|---|---|
| End point type | Secondary |

End point timeframe:

Baseline up to 8 weeks

| End point values | Placebo Controlled Period (CP) plus BSC | Bermekimab (Xilonix) plus BSC | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 102 | 207 | | |
| Units: picograms per milliliter (pg/mL) | | | | |
| arithmetic mean (standard deviation) | 9.9 (± 2.7) | 1.6 (± 1.9) | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in Platelet Count up to 8 Weeks

| | |
|---|---|
| End point title | Change from Baseline in Platelet Count up to 8 Weeks |

End point description:

Change in platelet count up to 8 weeks was reported. mITT population was defined as all randomized subjects who received at least one infusion of the study drug.

| | |
|---|---|
| End point type | Secondary |

End point timeframe:

Baseline up to 8 Weeks

| End point values | Placebo Controlled Period (CP) plus BSC | Bermekimab (Xilonix) plus BSC | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 102 | 207 | | |
| Units: 1000 per cubic millimeter (mm^-3) | | | | |
| arithmetic mean (standard deviation) | 39.53 (± 7.56) | 13.45 (± 5.33) | | |

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to 8 weeks

Adverse event reporting additional description:

Safety analysis set included enrolled subjects receiving at least one dose of the study drug.

| | |
|---|---|
| Assessment type | Non-systematic |

### Dictionary used

| | |
|---|---|
| Dictionary name | MedDRA |
| Dictionary version | 18.0 |

### Reporting groups

| | |
|---|---|
| Reporting group title | Placebo (CP) plus BSC |

Reporting group description:

Subjects received matching Placebo via intravenous (IV) injection once every 2 weeks (one cycle) for a total of 4 infusions (four cycles). Best supportive care (BSC) is defined as those measures intended to provide palliation of symptoms and improve quality of life. This included, but is not limited to, psychological support, dietary advice, exercise advice, antibiotics, anti-emetics, and analgesia.

| | |
|---|---|
| Reporting group title | Bermekimab plus BSC |

Reporting group description:

Subjects received an intravenous (IV) injection of Bermekimab 7.5 milligrams per kilograms (mg/kg) once every 2 weeks (Cycle 1) for a total of 4 infusions (four cycles). BSC is defined as those measures intended to provide palliation of symptoms and improve quality of life. This included, but is not limited to, psychological support, dietary advice, exercise advice, antibiotics, anti-emetics, and analgesia.

| | |
|---|---|
| Reporting group title | Placebo to Bermekimab (after CP) |

Reporting group description:

Subjects who received Placebo at Week 0, 2, 4, and 6 in CP received Bermekimab 7.5 mg/kg IV injection at Week 8 and every two weeks onwards.

| | |
|---|---|
| Reporting group title | Bermekimab (after CP) |

Reporting group description:

Subjects who received Bermekimab in CP were randomized to the control arm received IV placebo at 7.5 mg/kg via IV injection once every 2 weeks (one cycle) for a total of 4 infusions (four cycles).

| Serious adverse events | Placebo (CP) plus BSC | Bermekimab plus BSC | Placebo to Bermekimab (after CP) |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 27 / 102 (26.47%) | 45 / 207 (21.74%) | 15 / 62 (24.19%) |
| number of deaths (all causes) | 14 | 23 | 11 |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Colorectal Cancer | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 4 / 207 (1.93%) | 1 / 62 (1.61%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 4 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Malignant Neoplasm Progression | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastases to Central Nervous System | | | |
| subjects affected / exposed | 2 / 102 (1.96%) | 1 / 207 (0.48%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastases to Liver | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastasis | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 1 / 207 (0.48%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastatic Neoplasm | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Deep Vein Thrombosis | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 2 / 207 (0.97%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Embolism | | | |
| subjects affected / exposed | 1 / 102 (0.98%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Surgical and medical procedures | | | |
| Chemotherapy | | | |
| subjects affected / exposed | 1 / 102 (0.98%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 1 / 102 (0.98%) | 1 / 207 (0.48%) | 2 / 62 (3.23%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Death | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 1 / 207 (0.48%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Disease Progression | | | |
| subjects affected / exposed | 4 / 102 (3.92%) | 7 / 207 (3.38%) | 5 / 62 (8.06%) |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 8 | 0 / 5 |
| deaths causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 1 |
| Fatigue | | | |
| subjects affected / exposed | 1 / 102 (0.98%) | 0 / 207 (0.00%) | 1 / 62 (1.61%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General Physical Health Deterioration | | | |
| subjects affected / exposed | 2 / 102 (1.96%) | 3 / 207 (1.45%) | 1 / 62 (1.61%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Multi-Organ Failure | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Obstruction | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 1 / 207 (0.48%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pain | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Pyrexia | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 1 / 62 (1.61%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| Hypersensitivity | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |
| subjects affected / exposed | 1 / 102 (0.98%) | 2 / 207 (0.97%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 4 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypoxia | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 1 / 207 (0.48%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pleural Effusion | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 1 / 207 (0.48%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary Embolism | | | |
| subjects affected / exposed | 1 / 102 (0.98%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory Failure | | | |
| subjects affected / exposed | 1 / 102 (0.98%) | 1 / 207 (0.48%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Investigations | | | |
| Alanine Aminotransferase Increased | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 1 / 207 (0.48%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Platelet Count Decreased | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Cervical Vertebral Fracture | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hip Fracture | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 1 / 207 (0.48%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Incisional Hernia | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lumbar Vertebral Fracture | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Stoma Site Haemorrhage | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Congenital, familial and genetic disorders | | | |
| Hydrocele | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Cardiopulmonary Failure | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 1 / 207 (0.48%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coronary Artery Disease | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myocardial Infarction | | | |
| subjects affected / exposed | 1 / 102 (0.98%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Cerebrovascular Accident | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 1 / 207 (0.48%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Headache | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 1 / 62 (1.61%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lateral Medullary Syndrome | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal Cord Compression | | | |
| subjects affected / exposed | 1 / 102 (0.98%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 4 / 102 (3.92%) | 3 / 207 (1.45%) | 2 / 62 (3.23%) |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 6 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ear and labyrinth disorders | | | |
| Vertigo | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 1 / 207 (0.48%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal Pain | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 1 / 207 (0.48%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anal Haemorrhage | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 1 / 207 (0.48%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ascites | | | |
| subjects affected / exposed | 1 / 102 (0.98%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Constipation | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 1 / 62 (1.61%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Gastrointestinal Haemorrhage | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal Obstruction | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 1 / 62 (1.61%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ileal Stenosis | | | |
| subjects affected / exposed | 1 / 102 (0.98%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ileus | | | |
| subjects affected / exposed | 2 / 102 (1.96%) | 0 / 207 (0.00%) | 1 / 62 (1.61%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Obstruction Gastric | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 1 / 62 (1.61%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis Acute | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal Haemorrhage | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 1 / 207 (0.48%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small Intestinal Obstruction | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 1 / 207 (0.48%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subileus | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 102 (0.00%) | 1 / 207 (0.48%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 1 / 102 (0.98%) | 1 / 207 (0.48%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Hepatic Failure | | | |
| subjects affected / exposed | 3 / 102 (2.94%) | 2 / 207 (0.97%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Jaundice | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 1 / 207 (0.48%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Acute Kidney Injury | | | |
| subjects affected / exposed | 1 / 102 (0.98%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemorrhage Urinary Tract | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 1 / 62 (1.61%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal Failure | | | |
| subjects affected / exposed | 1 / 102 (0.98%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal Impairment | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 102 (0.00%) | 1 / 207 (0.48%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary Retention | | | |
| subjects affected / exposed | 1 / 102 (0.98%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Endocrine disorders | | | |
| Hypopituitarism | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 1 / 62 (1.61%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Muscular Weakness | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 1 / 62 (1.61%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal Pain | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 1 / 207 (0.48%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal Pain | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Abdominal Abscess | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Bronchopneumonia | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 1 / 207 (0.48%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cystitis | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 1 / 102 (0.98%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infection | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peritonitis | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 1 / 207 (0.48%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyonephrosis | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 1 / 207 (0.48%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory Tract Infection | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper Respiratory Tract Infection | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 1 / 207 (0.48%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 102 (0.00%) | 1 / 207 (0.48%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 2 / 207 (0.97%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperkalaemia | | | |
| subjects affected / exposed | 0 / 102 (0.00%) | 0 / 207 (0.00%) | 0 / 62 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| **Serious adverse events** | Bermekimab (after CP) | | |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 50 / 138 (36.23%) | | |
| number of deaths (all causes) | 31 | | |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Colorectal Cancer | | | |
| subjects affected / exposed | 7 / 138 (5.07%) | | |
| occurrences causally related to treatment / all | 0 / 8 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Malignant Neoplasm Progression | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Metastases to Central Nervous System | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Metastases to Liver | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 138 (0.72%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Metastasis | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Metastatic Neoplasm | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vascular disorders | | | |
| Deep Vein Thrombosis | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Embolism | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Surgical and medical procedures | | | |
| Chemotherapy | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Death | | | |
| subjects affected / exposed | 2 / 138 (1.45%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 2 | | |

| | | | |
|---|---|---|---|
| Disease Progression | | | |
| subjects affected / exposed | 12 / 138 (8.70%) | | |
| occurrences causally related to treatment / all | 0 / 12 | | |
| deaths causally related to treatment / all | 0 / 2 | | |
| Fatigue | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| General Physical Health Deterioration | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Multi-Organ Failure | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Obstruction | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pain | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pyrexia | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Immune system disorders | | | |
| Hypersensitivity | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Respiratory, thoracic and mediastinal | | | |

| | | | | |
|---|---|---|---|---|
| disorders | | | | |
| Dyspnoea | | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hypoxia | | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pleural Effusion | | | | |
| subjects affected / exposed | 2 / 138 (1.45%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pneumonitis | | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pulmonary Embolism | | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Respiratory Failure | | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Investigations | | | | |
| Alanine Aminotransferase Increased | | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Platelet Count Decreased | | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |

| | | | |
|---|---|---|---|
| Injury, poisoning and procedural complications | | | |
| Cervical Vertebral Fracture | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hip Fracture | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Incisional Hernia | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Lumbar Vertebral Fracture | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Stoma Site Haemorrhage | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Congenital, familial and genetic disorders | | | |
| Hydrocele | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cardiac disorders | | | |
| Cardiopulmonary Failure | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Coronary Artery Disease | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 138 (0.72%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Myocardial Infarction | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Nervous system disorders | | | |
| Cerebrovascular Accident | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Headache | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Lateral Medullary Syndrome | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Spinal Cord Compression | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Syncope | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 3 / 138 (2.17%) | | |
| occurrences causally related to treatment / all | 0 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Ear and labyrinth disorders | | | |

| | | | | |
|---|---|---|---|---|
| Vertigo | | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastrointestinal disorders | | | | |
| Abdominal Pain | | | | |
| subjects affected / exposed | 5 / 138 (3.62%) | | | |
| occurrences causally related to treatment / all | 0 / 5 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Anal Haemorrhage | | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Ascites | | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Constipation | | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Diarrhoea | | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastrointestinal Haemorrhage | | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastrointestinal Obstruction | | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Ileal Stenosis | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 138 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Ileus | | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Obstruction Gastric | | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pancreatitis Acute | | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Rectal Haemorrhage | | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Small Intestinal Obstruction | | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Subileus | | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Vomiting | | | | |
| subjects affected / exposed | 2 / 138 (1.45%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hepatobiliary disorders | | | | |
| Hepatic Failure | | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 138 (0.72%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Jaundice | | | |
| subjects affected / exposed | 2 / 138 (1.45%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Renal and urinary disorders | | | |
| Acute Kidney Injury | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Haemorrhage Urinary Tract | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Renal Failure | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Renal Impairment | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Urinary Retention | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Endocrine disorders | | | |

| | | | | |
|---|---|---|---|---|
| Hypopituitarism | | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Musculoskeletal and connective tissue disorders | | | | |
| Muscular Weakness | | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Musculoskeletal Pain | | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Spinal Pain | | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Infections and infestations | | | | |
| Abdominal Abscess | | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Bronchitis | | | | |
| subjects affected / exposed | 2 / 138 (1.45%) | | | |
| occurrences causally related to treatment / all | 1 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Bronchopneumonia | | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cystitis | | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |

| | | | | |
|---|---|---|---|---|
| Gastroenteritis | | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Infection | | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Peritonitis | | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pyonephrosis | | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Respiratory Tract Infection | | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Upper Respiratory Tract Infection | | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Urosepsis | | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Metabolism and nutrition disorders | | | | |
| Dehydration | | | | |
| subjects affected / exposed | 0 / 138 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hyperkalaemia | | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 138 (0.72%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 5 %

| **Non-serious adverse events** | Placebo (CP) plus BSC | Bermekimab plus BSC | Placebo to Bermekimab (after CP) |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 54 / 102 (52.94%) | 122 / 207 (58.94%) | 39 / 62 (62.90%) |
| Investigations | | | |
| Weight Decreased | | | |
| subjects affected / exposed | 7 / 102 (6.86%) | 20 / 207 (9.66%) | 7 / 62 (11.29%) |
| occurrences (all) | 8 | 21 | 8 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 6 / 102 (5.88%) | 16 / 207 (7.73%) | 5 / 62 (8.06%) |
| occurrences (all) | 6 | 27 | 8 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 9 / 102 (8.82%) | 18 / 207 (8.70%) | 11 / 62 (17.74%) |
| occurrences (all) | 9 | 21 | 15 |
| Fatigue | | | |
| subjects affected / exposed | 11 / 102 (10.78%) | 24 / 207 (11.59%) | 8 / 62 (12.90%) |
| occurrences (all) | 15 | 29 | 8 |
| Oedema Peripheral | | | |
| subjects affected / exposed | 8 / 102 (7.84%) | 21 / 207 (10.14%) | 3 / 62 (4.84%) |
| occurrences (all) | 8 | 26 | 3 |
| Pyrexia | | | |
| subjects affected / exposed | 5 / 102 (4.90%) | 9 / 207 (4.35%) | 2 / 62 (3.23%) |
| occurrences (all) | 5 | 9 | 2 |
| Gastrointestinal disorders | | | |
| Ascites | | | |
| subjects affected / exposed | 8 / 102 (7.84%) | 11 / 207 (5.31%) | 3 / 62 (4.84%) |
| occurrences (all) | 8 | 13 | 3 |
| Constipation | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 7 / 102 (6.86%) | 19 / 207 (9.18%) | 4 / 62 (6.45%) |
| occurrences (all) | 7 | 22 | 4 |
| Diarrhoea | | | |
| subjects affected / exposed | 2 / 102 (1.96%) | 9 / 207 (4.35%) | 3 / 62 (4.84%) |
| occurrences (all) | 4 | 10 | 4 |
| Nausea | | | |
| subjects affected / exposed | 12 / 102 (11.76%) | 18 / 207 (8.70%) | 2 / 62 (3.23%) |
| occurrences (all) | 12 | 26 | 2 |
| Vomiting | | | |
| subjects affected / exposed | 5 / 102 (4.90%) | 13 / 207 (6.28%) | 2 / 62 (3.23%) |
| occurrences (all) | 5 | 18 | 2 |
| Abdominal Pain | | | |
| subjects affected / exposed | 14 / 102 (13.73%) | 32 / 207 (15.46%) | 6 / 62 (9.68%) |
| occurrences (all) | 16 | 32 | 6 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 3 / 102 (2.94%) | 4 / 207 (1.93%) | 1 / 62 (1.61%) |
| occurrences (all) | 4 | 4 | 1 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 4 / 102 (3.92%) | 3 / 207 (1.45%) | 4 / 62 (6.45%) |
| occurrences (all) | 4 | 5 | 4 |
| Pain in Extremity | | | |
| subjects affected / exposed | 2 / 102 (1.96%) | 8 / 207 (3.86%) | 4 / 62 (6.45%) |
| occurrences (all) | 2 | 8 | 4 |
| Infections and infestations | | | |
| Urinary Tract Infection | | | |
| subjects affected / exposed | 3 / 102 (2.94%) | 9 / 207 (4.35%) | 2 / 62 (3.23%) |
| occurrences (all) | 4 | 10 | 2 |
| Metabolism and nutrition disorders | | | |
| Decreased Appetite | | | |
| subjects affected / exposed | 9 / 102 (8.82%) | 17 / 207 (8.21%) | 4 / 62 (6.45%) |
| occurrences (all) | 9 | 17 | 4 |

| **Non-serious adverse events** | Bermekimab (after CP) | | |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 87 / 138 (63.04%) | | |
| Investigations | | | |
| Weight Decreased | | | |
| subjects affected / exposed | 16 / 138 (11.59%) | | |
| occurrences (all) | 21 | | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 11 / 138 (7.97%) | | |
| occurrences (all) | 21 | | |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 17 / 138 (12.32%) | | |
| occurrences (all) | 27 | | |
| Fatigue | | | |
| subjects affected / exposed | 20 / 138 (14.49%) | | |
| occurrences (all) | 23 | | |
| Oedema Peripheral | | | |
| subjects affected / exposed | 9 / 138 (6.52%) | | |
| occurrences (all) | 9 | | |
| Pyrexia | | | |
| subjects affected / exposed | 12 / 138 (8.70%) | | |
| occurrences (all) | 14 | | |
| Gastrointestinal disorders | | | |
| Ascites | | | |
| subjects affected / exposed | 9 / 138 (6.52%) | | |
| occurrences (all) | 10 | | |
| Constipation | | | |
| subjects affected / exposed | 11 / 138 (7.97%) | | |
| occurrences (all) | 11 | | |
| Diarrhoea | | | |
| subjects affected / exposed | 7 / 138 (5.07%) | | |
| occurrences (all) | 7 | | |
| Nausea | | | |
| subjects affected / exposed | 8 / 138 (5.80%) | | |
| occurrences (all) | 10 | | |
| Vomiting | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 5 / 138 (3.62%) | | |
| occurrences (all) | 7 | | |
| Abdominal Pain | | | |
| subjects affected / exposed | 22 / 138 (15.94%) | | |
| occurrences (all) | 28 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 8 / 138 (5.80%) | | |
| occurrences (all) | 9 | | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 1 / 138 (0.72%) | | |
| occurrences (all) | 1 | | |
| Pain in Extremity | | | |
| subjects affected / exposed | 4 / 138 (2.90%) | | |
| occurrences (all) | 4 | | |
| Infections and infestations | | | |
| Urinary Tract Infection | | | |
| subjects affected / exposed | 8 / 138 (5.80%) | | |
| occurrences (all) | 8 | | |
| Metabolism and nutrition disorders | | | |
| Decreased Appetite | | | |
| subjects affected / exposed | 15 / 138 (10.87%) | | |
| occurrences (all) | 17 | | |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported